<div align="center">
  <img src="assets/banner.svg" alt="Awesome AI Vaccine Design Engineer Banner" width="100%">
</div>

# 🧬 Awesome AI Vaccine Design Engineer Interview Q&A 🧪
<div align="center">
<a href="https://github.com/ishandutta2007/Awesome-Awesome-Awesome"><img src="https://img.shields.io/badge/Awesome-%E2%9C%94-blueviolet?style=flat-square&logo=github" alt="Awesome"/></a><a href="https://discord.gg/jc4xtF58Ve"><img src="https://img.shields.io/badge/Discord-5865F2?style=for-the-badge&logo=discord&logoColor=white" alt="Discord" /></a><a href="https://github.com/ishandutta2007"><img alt="GitHub followers" src="https://img.shields.io/github/followers/ishandutta2007?label=Follow" /></a>
</div>

A comprehensive, community-curated collection of **185+ interview questions and answers** for **AI Vaccine Design Engineer** roles — professionals who apply machine learning and structural/computational biology to antigen design, epitope prediction, immunogen optimization, and vaccine platform engineering, sitting at the intersection of immunology, structural biology, computational modeling, and vaccine development regulatory science.

## 📌 🦠 Overview

**AI Vaccine Design Engineers** build and apply computational tools across the vaccine development pipeline — B-cell and T-cell epitope prediction, antigen/immunogen structure-based design, HLA binding and population coverage modeling, viral/pathogen evolution and escape prediction, and platform-specific optimization (mRNA, viral vector, protein subunit) — while navigating the unique constraints of immunological complexity (polymorphic HLA, pathogen antigenic variability) and vaccine-specific regulatory and clinical development pathways.

This repository covers:
- ✅ Immunology fundamentals for computational scientists
- ✅ B-cell epitope prediction and antigen structure-based design
- ✅ T-cell epitope prediction and HLA binding/population coverage modeling
- ✅ Pathogen evolution, antigenic variability, and escape prediction
- ✅ Vaccine platform-specific design considerations (mRNA, viral vector, protein subunit, VLP)
- ✅ Immunogenicity prediction, model validation, and reverse vaccinology pipelines
- ✅ Regulatory pathways and clinical development for vaccines
- ✅ Cross-functional collaboration and industry landscape

**Estimated preparation time:** 30–50 hours
**Interview duration:** Typically 4–6 rounds (3–5 hours total), often including a structural biology/modeling round and an immunology domain round

---

## 📚 📁 Repository Structure

```
Awesome-AI-Vaccine-Design-Engineer-Interview-QA/
├── README.md
├── CONTRIBUTING.md
├── LICENSE
├── topics/
│   ├── 01-Immunology-Fundamentals.md
│   ├── 02-B-Cell-Epitope-Antigen-Design.md
│   ├── 03-T-Cell-Epitope-HLA-Binding-Prediction.md
│   ├── 04-Pathogen-Evolution-Escape-Prediction.md
│   ├── 05-Vaccine-Platform-Specific-Design.md
│   ├── 06-Immunogenicity-Prediction-Reverse-Vaccinology.md
│   ├── 07-Model-Validation-Experimental-Integration.md
│   ├── 08-Structural-Biology-Computational-Methods.md
│   ├── 09-Regulatory-Clinical-Development.md
│   ├── 10-Cross-Functional-Collaboration.md
│   ├── 11-Troubleshooting-Case-Studies.md
│   └── 12-Industry-Context-Pandemic-Preparedness.md
├── docs/
│   ├── glossary.md
│   ├── resources.md
│   └── roadmap.md
└── .gitignore
```

---

## 🎯 📊 Topic Breakdown

| # | Topic | Focus Area | Q&A Count |
|---|-------|-----------|-----------|
| 01 | Immunology Fundamentals | Innate/adaptive immunity, antibody/TCR biology | 16 |
| 02 | B-Cell Epitope & Antigen Design | Conformational epitopes, structure-based immunogen design | 16 |
| 03 | T-Cell Epitope & HLA Binding Prediction | MHC-I/II prediction, population coverage | 16 |
| 04 | Pathogen Evolution & Escape Prediction | Antigenic drift/shift, variant forecasting | 15 |
| 05 | Vaccine Platform-Specific Design | mRNA, viral vector, protein subunit, VLP considerations | 15 |
| 06 | Immunogenicity Prediction & Reverse Vaccinology | End-to-end computational vaccine design pipelines | 15 |
| 07 | Model Validation & Experimental Integration | Wet-lab immunoassay validation, active learning | 15 |
| 08 | Structural Biology & Computational Methods | Structure prediction, molecular dynamics, docking | 15 |
| 09 | Regulatory & Clinical Development | FDA/EMA vaccine pathways, correlates of protection | 14 |
| 10 | Cross-Functional Collaboration | Working with immunologists, structural biologists, clinicians | 14 |
| 11 | Troubleshooting & Case Studies | Prediction failures, validation mismatches | 14 |
| 12 | Industry Context & Pandemic Preparedness | Market landscape, platform trends, rapid response | 13 |
| | **TOTAL** | | **178** |

---

## 🚀 🛤️ How to Use This Repository

### Study Plan (6 Weeks)
- **Week 1:** Topics 01–02 (Immunology Fundamentals + B-Cell Epitope/Antigen Design)
- **Week 2:** Topics 03–04 (T-Cell Epitope/HLA + Pathogen Evolution)
- **Week 3:** Topics 05–06 (Vaccine Platforms + Reverse Vaccinology)
- **Week 4:** Topics 07–08 (Model Validation + Structural Biology Methods)
- **Week 5:** Topics 09–10 (Regulatory/Clinical + Cross-Functional Collaboration)
- **Week 6:** Topics 11–12 + Mock Interviews + Review

---

## 📖 ⚡ Quick Start Example

**From Topic 04: Pathogen Evolution & Escape Prediction**

> **Q: Your model predicts a specific viral surface protein region as a strong vaccine antigen target based on high predicted immunogenicity and broad HLA population coverage, but the region shows a high historical mutation rate in circulating strain surveillance data. How do you reconcile these findings and inform target prioritization?**
>
> **A:** This is a genuine tension between immunogenicity and antigenic stability that a well-designed target prioritization framework must explicitly weigh rather than treating immunogenicity as the sole criterion. High historical mutation rate at a targeted epitope suggests either ongoing immune-driven selective pressure (the pathogen is actively evolving to escape existing immunity at this site, making a vaccine targeting it prone to being outpaced by viral evolution) or simply higher baseline tolerance for variation at that structural position (less functionally constrained, and thus more likely to escape vaccine-induced immune pressure without a fitness cost to the pathogen). The reconciliation requires layering conservation/constraint analysis (is this site functionally essential, e.g., part of a receptor-binding domain that can't easily mutate without fitness cost) alongside the mutation rate data — a highly immunogenic but functionally unconstrained, rapidly-mutating site is a poor durable vaccine target regardless of its short-term immunogenicity prediction, while a site combining strong immunogenicity with high functional constraint (mutation would impair pathogen fitness) is a substantially better candidate for durable protection.

---

## 🤝 🌱 Contributing

See **[CONTRIBUTING.md](CONTRIBUTING.md)** for guidelines.

**Areas seeking contributions:**
- Structure-based immunogen design deep dives (e.g., epitope scaffolding, nanoparticle display)
- mRNA vaccine sequence/UTR optimization computational approaches
- Universal/broadly-protective vaccine design case studies (universal flu, pan-coronavirus)
- De-identified computational-to-clinical vaccine candidate translation case studies

---

## 📜 ⚖️ License
MIT License — see **[LICENSE](LICENSE)**.

---

**Last Updated:** July 2026
**Contributors:** 1 (growing!)
# Awesome-AI-Vaccine-Design-Engineer-Interview-QA

##  Star History
<div align="center">
<a href="https://www.star-history.com/?repos=ishandutta2007%2FAwesome-AI-Vaccine-Design-Engineer-Interview-QA&type=date&legend=bottom-right">
<picture>
<source media="(prefers-color-scheme: dark)" srcset="https://api.star-history.com/chart?repos=ishandutta2007/Awesome-AI-Vaccine-Design-Engineer-Interview-QA&type=date&theme=dark&legend=bottom-right" />
<source media="(prefers-color-scheme: light)" srcset="https://api.star-history.com/chart?repos=ishandutta2007/Awesome-AI-Vaccine-Design-Engineer-Interview-QA&type=date&legend=bottom-right" />
<img alt="Star History Chart" src="https://api.star-history.com/chart?repos=ishandutta2007/Awesome-AI-Vaccine-Design-Engineer-Interview-QA&type=date&legend=bottom-right" />
</picture>
</a>
</div>
